POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH

Their core work

Polymun Scientific is an Austrian biotech SME in Klosterneuburg that develops and produces biopharmaceuticals, with expertise in vaccines, recombinant proteins, and lipid-based delivery systems. They bring GMP-grade bioprocessing capacity and act as a contract development partner that helps move academic discoveries toward clinical-grade biologics. Their two H2020 engagements — an HIV vaccine initiative and a microbial protein production training network — reflect that industrial translation role.

What they specialise in

How they've shifted over time

With only two H2020 projects it is hard to claim a dramatic shift, but a direction is visible. Their earlier engagement (EAVI2020, starting 2015) was clinical-translational, focused on HIV vaccine development. Their later engagement (Secreters, starting 2019) moved toward platform technologies — microbial expression hosts, super-secretion systems, and industrial enzymes — suggesting a broadening from a single therapeutic area into generalisable bioprocessing tools and talent pipelines.

Polymun appears to be widening its offer from specific vaccine projects toward reusable production platforms and trained talent, making them relevant to any consortium that needs to scale a biologic from lab to clinic.

How they like to work

Polymun has not coordinated any H2020 project in this dataset — they enter consortia as a participant or third-party partner, contributing specialised industrial know-how rather than leading the scientific agenda. Despite only two projects, they have worked with 41 distinct partners across 15 countries, indicating they plug into large, broad consortia rather than small bilateral collaborations. For a prospective partner this means they are a reliable specialist contributor who fits into an existing plan rather than driving it.

41 unique partners across 15 countries from just two projects — a strong indicator that both consortia were large pan-European ones. No single country dominates the collaboration pattern beyond the standard Western European health-research axis.

What sets them apart

Polymun is one of the few European SMEs that can offer end-to-end biopharmaceutical development alongside GMP-compatible production thinking, which is why large clinical consortia invite them in. They sit in the narrow space between academic bioprocess research and full contract manufacturing — smaller and more flexible than pharma primes, but more industrially capable than a university lab. If a consortium needs someone who can actually make the vaccine or protein after the biology is worked out, they are a natural pick.

Highlights from their portfolio

• EAVI2020
  Multi-year, EUR 3.5M-funded flagship European HIV vaccine initiative — a high-visibility clinical translation effort.
• Secreters
  MSCA doctoral training network on next-generation microbial expression hosts, showing Polymun also trains the next cohort of industrial biotech researchers.